ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2025

Corrigendum to Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.